 |
|
Risk of the "Androgen Deprivation Syndrome" in Men Receiving Androgen Deprivation for Prostate Cancer
Vahakn B. Shahinian, MD, MS;
Yong-Fang Kuo, PhD;
Jean L. Freeman, PhD;
James S. Goodwin, MD
Arch Intern Med. 2006;166:465-471.
Background: Androgen deprivation therapy for prostate cancer has been associated with a spectrum of adverse effects, such as depression, memory difficulties, and fatigue, termed the androgen deprivation syndrome. Primary care physicians providing follow-up care for men with prostate cancer will be faced with managing these effects. We therefore sought to estimate the incidence of these effects and, by using a control group, ascertain whether these effects were related to androgen deprivation itself.
Methods: We assessed the risk of physician diagnoses of depression, cognitive impairment, or constitutional symptoms in Medicare data following androgen deprivation using a sample of 50 613 men with incident prostate cancer and 50 476 men without cancer, from 1992 through 1997, in the linked Surveillance, Epidemiology, and End Results–Medicare database. Cox proportional hazards regression was used to adjust for confounding variables.
Results: Of men surviving at least 5 years after diagnosis, 31.3% of those receiving androgen deprivation developed at least 1 depressive, cognitive, or constitutional diagnosis compared with 23.7% in those who did not (P<.001). After adjustment for variables such as comorbidity, tumor characteristics, and age, the risks associated with androgen deprivation were substantially reduced or abolished: relative risk (RR) for depression diagnosis, 1.08 (95% confidence interval [CI], 1.02-1.15); RR for cognitive impairment, 0.99 (95% CI, 0.94-1.04); and RR for constitutional symptoms, 1.17 (95% CI, 1.13-1.22).
Conclusion: Depressive, cognitive, and constitutional disorders occur more commonly in patients receiving androgen deprivation, but this appears to be primarily because patients receiving androgen deprivation are older and have more comorbid conditions and more advanced cancers.
Author Affiliations: Departments of Internal Medicine (Drs Shahinian, Kuo, Freeman, and Goodwin) and Preventive Medicine and Community Health (Drs Kuo, Freeman, and Goodwin), and Sealy Center on Aging (Drs Shahinian, Kuo, Freeman, and Goodwin), University of Texas Medical Branch, Galveston.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Do General Dimensions of Quality of Life Add Clinical Value to Symptom Data?
Moinpour et al.
J Natl Cancer Inst Monogr 2007;2007:31-38.
ABSTRACT
| FULL TEXT
Clinically localised prostate cancer
Wilt and Thompson
BMJ 2006;333:1102-1106.
FULL TEXT
Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist.
Shahinian et al.
JNCI J Natl Cancer Inst 2006;98:839-845.
ABSTRACT
| FULL TEXT
|
